Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
复制标题
DOI：
10.1056/nejmoa1610497
复制
发表时间：
2016-12-29
期刊：
影响因子：
--
通讯作者：
Badie B
中科院分区：
文献类型：
--
作者：
Brown CE;Alizadeh D;Starr R;Weng L;Wagner JR;Naranjo A;Ostberg JR;Blanchard MS;Kilpatrick J;Simpson J;Kurien A;Priceman SJ;Wang X;Harshbarger TL;D'Apuzzo M;Ressler JA;Jensen MC;Barish ME;Chen M;Portnow J;Forman SJ;Badie B
A patient with recurrent multifocal glioblastoma received chimeric antigen receptor (CAR)–engineered T cells targeting the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). Multiple infusions of CAR T cells were administered over 220 days through two intracranial delivery routes — infusions into the resected tumor cavity followed by infusions into the ventricular system. Intracranial infusions of IL13Rα2-targeted CAR T cells were not associated with any toxic effects of grade 3 or higher. After CAR T-cell treatment, regression of all intracranial and spinal tumors was observed, along with corresponding increases in levels of cytokines and immune cells in the cerebrospinal fluid. This clinical response continued for 7.5 months after the initiation of CAR T-cell therapy.
